| |
|
|
We
Are Changing the Face of Drug Discovery |
|
| |
|
|
|
|
|
|
|
| |
|
|
 |
|
|
With
a revolutionary new approach, Serometrix is working to help discover
better life saving pharmaceuticals with lower development costs
than ever before. Emulating nature to solve the biological complexity
of intractable drug targets, our team finds itself with an exciting
and rewarding scientific directive. Combining an early stage collaborative
business model that can lower risks and shorten development times,
we are proud to be part of the union of small biotech innovation
and big pharma expertise. It is an idea whose time has finally come. |
|
| |
|
|
|
|
| |
|
|
Company
Overview |
|
| |
|
|
Serometrix
is an in silico Drug Discovery company that delivers novel
families of targeted lead stage molecules for development by strategic
partners. The proprietary Serometrix discovery platform identifies
and emulates wild type protein interactions, providing detailed
biological knowledge and delivering synthetic lead stage molecules
for licensure and/or co-development. |
|
| |
|
|
The
company offers significant value to the drug discovery and development
process by providing: |
|
| |
|
|
-
a
proprietary in silico method for identifying protein-protein
interaction "hot spots", complementing x-ray crystallography
and antibody mapping techniques
-
a proprietary in silico method that yields initial
regulatory prototype compounds (wild type ligands) for orthosteric
and allosteric manipulation of these "hot spots"
-
an
iterative in silico/in vitro strategy which helps
define the structure activity relationship (SAR) at, or near,
these biologically relevant "hot spots"
-
a
family of "induced fit & structure optimized"
lead stage molecules which can be further preclinically developed,
or utilized by development partners to initiate more efficient
and commercially relevant HTS strategies
-
an all encompassing breadth of associated biological IP, including
targets, ligand families, and target specific biological processes
which can be used by development partners for tremendous competitive
advantage
|
|
|
